Logo for TransCode Therapeutics Inc

TransCode Therapeutics Investor Relations Material

Latest events

Logo for TransCode Therapeutics

Q3 2024

14 Nov, 2024
Logo for TransCode Therapeutics

Q4 2023

3 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from TransCode Therapeutics Inc

Access all reports
TransCode Therapeutics Inc. is a U.S.-based biotechnology company focused on developing RNA-targeted therapies for treating cancer. The company uses its proprietary TTX platform to design and deliver RNA-based therapeutics aimed at addressing previously undruggable cancer targets. TransCode’s research primarily involves preclinical and clinical development of treatments for metastatic and solid tumors, aiming to improve precision and efficacy in cancer treatment. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.